11,699 Shares in uniQure (NASDAQ:QURE) Bought by Quarry LP

Quarry LP purchased a new position in uniQure (NASDAQ:QURE) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 11,699 shares of the biotechnology company’s stock, valued at approximately $58,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Personalized Indexing Management LLC lifted its position in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of uniQure by 14.6% during the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 8,642 shares in the last quarter. RTW Investments LP bought a new position in shares of uniQure during the 3rd quarter valued at approximately $49,000. Finally, Atria Investments Inc purchased a new position in shares of uniQure in the third quarter valued at $53,000. Institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

QURE has been the subject of several research reports. Raymond James reiterated an “outperform” rating and set a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. StockNews.com raised shares of uniQure to a “sell” rating in a report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Royal Bank of Canada lowered their price objective on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

uniQure Stock Performance

QURE stock opened at $7.30 on Tuesday. The firm has a market cap of $355.56 million, a price-to-earnings ratio of -1.47 and a beta of 0.89. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s fifty day simple moving average is $6.20 and its two-hundred day simple moving average is $6.08.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Analysts predict that uniQure will post -3.74 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.